Oral Transmucosal Drugs Market Size, Share, Industry Trends and Forecast to 2030

Oral Transmucosal Drugs Market Size & CAGR in 2021:

The global oral transmucosal drugs market is expected to have a growth rate of 5.8% CAGR from 2021 to 2026. The market size is projected to reach USD 14.5 billion by the end of 2021. The increasing prevalence of chronic diseases and the growing demand for non-invasive drug delivery systems are driving the market growth.

COVID-19 Impact on the Oral Transmucosal Drugs Market:

The COVID-19 pandemic has had a mixed impact on the oral transmucosal drugs market. While there has been a disruption in the supply chain and manufacturing processes due to lockdowns and restrictions, there has also been an increased demand for non-invasive drug delivery systems, including oral transmucosal drugs, as they offer convenience and safety during the pandemic.

Oral Transmucosal Drugs Dynamics:

The dynamics of the oral transmucosal drugs market are influenced by factors such as technological advancements, increasing prevalence of chronic diseases, and the growing geriatric population. The market is also driven by the demand for faster drug delivery and improved patient compliance.

Segments and Related Analysis:

The oral transmucosal drugs market can be segmented based on drug type, dosage form, application, and region. Drug types include opioids, antiemetics, NSAIDs, and others. Dosage forms include films, patches, tablets, and sprays. Applications include pain management, nausea/vomiting, migraine, and others.

By Region Analysis:

In terms of region, North America currently leads the oral transmucosal drugs market due to the presence of key market players, technological advancements, and high healthcare expenditure. However, the Asia-Pacific region is expected to witness the highest growth rate during the forecast period due to increasing healthcare infrastructure and rising awareness about oral transmucosal drug delivery systems.

Key Market Players and Competitive Landscape:

Some of the key players in the oral transmucosal drugs market include Pfizer Inc., GlaxoSmithKline plc, Johnson & Johnson Services, Inc., Novartis AG, and Merck & Co., Inc. These companies are focusing on strategic partnerships, product launches, and acquisitions to gain a competitive edge in the market.

Recent Happenings in the Oral Transmucosal Drugs Market:

- In September 2021, Pfizer Inc. announced the launch of a new oral transmucosal drug for pain management. - In June 2021, GlaxoSmithKline plc entered into a partnership with a biotech company to develop innovative oral transmucosal drugs. - In March 2021, Johnson & Johnson Services, Inc. received FDA approval for a new oral transmucosal drug for migraine treatment. - In January 2021, Novartis AG acquired a pharmaceutical company specializing in oral transmucosal drug delivery systems.